The Canada-U.S. trade fight has reached one of its most sensitive industries. As of 12:01 a.m. Eastern time on September 29, 2026, the United States’ Section 232 tariff regime expanded to covered patented pharmaceuticals and associated ingredients from companies that had previously been given more time to comply. For Canadian-origin products that fall within the measure and do not qualify for another exception, the applicable U.S. tariff rate can now reach 100%.
The significant detail for Canadian exporters is that CUSMA does not provide a blanket escape route. Canadian government guidance specifically says there is no CUSMA-compliant exemption from these pharmaceutical Section 232 tariffs. Still, this is not a 100% tariff on every medicine made in Canada: generics are currently exempt, while company agreements, product categories and other special treatment can produce much lower rates.
The September 29 Deadline Changes the Rules for More Drugmakers
The pharmaceutical tariff did not arrive everywhere at once. President Donald Trump’s April 2 proclamation created a staggered implementation schedule. Products associated with companies identified in Annex III faced the new system beginning July 31, while other affected companies received until September 29. That second deadline has now arrived, making the measure relevant to a much broader universe of imported patented medicines and pharmaceutical ingredients.
U.S. Customs and Border Protection instructed importers that the previous temporary provision for those other companies applied only through September 28. Beginning at 12:01 a.m. Eastern time on September 29, affected entries are subject to the new tariff structure when entered for consumption or withdrawn from a warehouse for consumption. CBP describes the headline 100% rate as the combined Column 1 and Section 232 rate. That distinction matters: the policy creates a tariff rate reaching 100%, rather than simply adding another 100 percentage points on top of every existing customs rate.
The Tariff Is Broad, but It Does Not Cover Every Pharmaceutical Shipment
The word “pharmaceutical” makes the measure sound almost universal, but the actual customs rules are considerably more precise. The U.S. framework targets covered patented finished pharmaceutical products as well as associated active pharmaceutical ingredients and key starting materials. September guidance from the Commerce Department further clarified that the definition is intended to capture finished pharmaceutical products, their APIs and the key starting materials used to make those APIs.
Several major categories sit outside the headline rate. Generic pharmaceutical products and their associated ingredients currently receive zero additional Section 232 duty. U.S.-origin pharmaceutical products imported back into the country are also excluded. Commerce additionally created zero-duty treatment for qualifying pharmaceutical products and ingredients brought in solely for clinical trials, research and development or other non-commercial applications. Taken together, those exceptions mean two boxes of medicine leaving Canadian facilities could receive very different customs treatment depending on their patent status, origin, intended use and the company behind them.
CUSMA Still Exists, but It Does Not Neutralize This Section 232 Duty
One of the most important distinctions for Canadian businesses is that the absence of an exemption does not mean CUSMA has vanished. The United States declined to renew the agreement in its current form during the July 1, 2026 joint review, but the Office of the U.S. Trade Representative said the agreement remains in force while the three countries deal with unresolved issues or until it is formally terminated.
That continued status does not shield covered pharmaceuticals from the Section 232 measure. Canada’s Trade Commissioner Service explicitly states that there is no CUSMA-compliant exemption for the patented-pharmaceutical tariff. U.S. Customs guidance reaches the issue from the other direction: goods eligible for preferential treatment under a listed free-trade agreement can still owe the pharmaceutical Chapter 99 duty in addition to whatever special base tariff treatment the trade agreement provides. In practical terms, being Canadian and CUSMA-qualifying does not automatically bring the Section 232 rate back to zero.
Canada Has Significant Pharmaceutical Exposure to the U.S. Market
The importance of the measure becomes clearer when the size of the existing trade relationship is considered. Innovation, Science and Economic Development Canada reports that Canadian pharmaceutical exports totalled about $14.5 billion in 2025. The United States accounted for 70.4% of those exports, making it by far Canada’s most important foreign market for the sector. The U.S. also supplied 32.4% of Canadian pharmaceutical imports that year.
That does not mean 70.4% of Canadian pharmaceutical exports suddenly face a 100% tariff. The Canadian export statistics include a much broader range of pharmaceutical activity than the U.S. measure’s covered patented products. Generics, certain specialty products and other exempt shipments have different treatment. Still, the trade concentration demonstrates why even a narrower tariff can matter. Canada’s pharmaceutical manufacturing industry employed roughly 35,700 people in 2025, with significant clusters around Toronto, Montreal and Vancouver. For facilities built around integrated North American supply chains, a new customs distinction can quickly become a production, pricing and investment issue.
The Same Drug Can Face Very Different Tariff Treatment Depending on Its Origin and Company
The headline rate is 100%, but the administration has built several alternative tracks into the system. Covered products originating in the European Union, Japan, South Korea, Switzerland or Liechtenstein generally receive a 15% rate under the proclamation. United Kingdom products have a 10% treatment, with the possibility of further reduction under the U.S.-UK pharmaceutical arrangement. Canada does not have an equivalent country-wide pharmaceutical rate cap.
Company decisions can matter just as much as geography. A manufacturer with a Commerce-approved plan to move qualifying production to the United States can receive a 20% rate under the framework, although that rate is scheduled to rise to 100% on April 2, 2030. Companies combining eligible onshoring arrangements with qualifying most-favoured-nation pricing agreements can receive zero tariff treatment through January 20, 2029. The rules also say that when a product qualifies for more than one treatment, the lowest applicable rate should generally be used. That creates a tariff map shaped by product, origin and corporate commitments rather than nationality alone.
Major Drugmakers Have Already Used Pricing and Investment Deals to Reduce Their Exposure
The Trump administration designed the tariff alongside another policy objective: encouraging drugmakers to reach pricing agreements with Washington and expand pharmaceutical production inside the United States. Reuters reported in April that 17 large pharmaceutical companies had ultimately announced agreements with the administration that linked most-favoured-nation drug pricing commitments and U.S. investment pledges with three-year exemptions from pharmaceutical import tariffs.
That structure creates a substantially different situation for large global companies that have already negotiated arrangements compared with smaller manufacturers that remain outside them. Reuters reported when the tariff was announced that smaller and mid-sized drug companies could be particularly exposed unless they secured similar agreements or shifted qualifying production toward the United States. For Canadian operations, the corporate ownership structure alone does not answer the tariff question. A Canadian plant belonging to a multinational with a qualifying U.S. agreement may have a different position from an independent Canadian producer shipping a patented product without one. Customs treatment increasingly depends on the details of the individual supply chain.
Canada Was Left Off a New Automatic Specialty-Drug Exemption List
A Commerce Department notice published just six days before the September 29 deadline added another important layer. Certain specialty pharmaceuticals can receive zero Section 232 duty if they come from specified jurisdictions. Eligible categories include orphan drugs, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapies, antibody-drug conjugates, certain chemical, biological, radiological and nuclear medical countermeasures, and animal-health products.
Commerce listed 19 eligible jurisdictions or groups: Argentina, Bangladesh, Cambodia, Ecuador, El Salvador, the European Union, Guatemala, India, Indonesia, Japan, Jordan, Malaysia, North Macedonia, South Korea, Switzerland and Liechtenstein, Taiwan, Thailand, the United Kingdom and Vietnam. Canada was not included. That does not necessarily close the door for every Canadian specialty medicine. Commerce has established a separate process allowing companies to request zero-duty treatment when a product meets an urgent U.S. health need. Applications are reviewed individually with input from Commerce, the U.S. Trade Representative and health officials, making the exemption possible but not automatic for Canadian-origin products.
A 100% Customs Tariff Does Not Automatically Mean Drugstore Prices Double
A tariff equal to the customs value sounds like it should translate directly into a doubling of a medicine’s retail price, but pharmaceutical pricing does not work that simply. Manufacturers, importers, wholesalers, insurers and other participants can absorb or redistribute some of the cost, while company-specific exemptions may prevent a tariff from being paid at all. The eventual impact can also depend on contracts, inventories, manufacturing margins and whether production can be shifted elsewhere.
Academic research illustrates why pass-through assumptions matter. A 2025 Health Affairs Scholar study modelled tariffs on imported active ingredients used in U.S.-manufactured generic drugs. Under one hypothetical 100% worldwide API tariff scenario, assuming APIs represented 30% of the finished drug price and the entire added tariff cost was passed through, the model produced an average price increase of 30%, or about $21.15 per prescription. That study examined generics and therefore is not a forecast for today’s patented-drug policy, under which generics are currently exempt. Its useful lesson is narrower: a 100% border tariff and a 100% patient-price increase are not equivalent concepts.
The September 29 Rules May Not Be the Final Version
Several parts of the pharmaceutical tariff regime remain deliberately adjustable. Commerce said the list of jurisdictions qualifying for specialty-drug relief may be changed through future notices. Companies can continue seeking urgent-health-need exemptions, and the government can modify company treatment when commitments are met—or, under the proclamation, potentially restore higher tariffs when promised onshoring commitments are not fulfilled.
Generics also deserve attention even though they are protected for now. The April proclamation directed the Commerce Secretary to report back within one year if circumstances suggest action on generic pharmaceuticals or their ingredients may be needed. Meanwhile, the preferential 20% treatment associated with qualifying onshoring plans is scheduled to become 100% on April 2, 2030, while certain zero-tariff company arrangements expire January 20, 2029. For Canadian pharmaceutical exporters, September 29 is therefore less a single finish line than the start of a more complicated customs environment—one in which tariff classifications, manufacturing location, patent status and negotiated corporate agreements increasingly determine access to the U.S. market.
